Aragen to operationalize Hyderabad formulation manufacturing facility by Jan 2023

The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting

Marksans to acquire Tevapharm's bulk formulations business

Plans to double its manufacturing footprint to bolster the growth

Everstone acquires controlling stake in Softgel Healthcare

Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.

Auretics Introduces its range of ayurvedic products

This includes Madhurodhi, HBP Care & LBP Care for sugar & BP patients

Bajaj Healthcare forays into the highly regulated - Opiate Processing Business for the GOI

The company plans to execute both these tenders at their API manufacturing unit located at Savli, Gujarat, India.

Glenmark Pharmaceuticals expand its OTC portfolio

The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world

Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for HIV in South Africa

This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.

Adroit BioMed launches Fortisil range of skincare products

Lupin receives USFDA approval for Pregabalin and Iloperidone

While Pregabalin will be manufactured at the Aurangabad facility, Iloperidone will be manufactured at the Goa facility

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo